Brief: Vistagen Announces Topline Results From Palisade-3 Phase 3 Study
17/12/2025 13:50
Dec 17 (Reuters) - VistaGen Therapeutics Inc VTGN.O: VISTAGEN ANNOUNCES TOPLINE RESULTS FROM PALISADE-3 PHASE 3 PUBLIC SPEAKING CHALLENGE STUDY OF FASEDIENOL FOR THE ACUTE TREATMENT OF SOCIAL ANXIETY DISORDER VISTAGEN THERAPEUTICS INC - STUDY DID NOT SHOW SIGNIFICANT IMPROVEMENT IN ANXIETY REDUCTION VISTAGEN THERAPEUTICS INC - FAVORABLE SAFETY DATA OF FASEDIENOL CONSISTENT WITH PREVIOUS TRIALS VISTAGEN THERAPEUTICS INC - CASH PRESERVATION MEASURES EXPECTED TO PROVIDE RUNWAY INTO 2027 Source text: ID:nBwbsFCZWa Further company coverage: VTGN.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Vistagen Therapeutics
See all newsBrief: Vistagen TherapeuticsSays Fasedienol Nasal Spray Well-Tolerated With No New Drug-Related Safety Findings After 12 Months
VistaGen Q1 revenue rises on licensing agreement expiration
Brief: VistaGen Q1 EPS USD -0.3
Vistagen Therapeutics Inc expected to post a loss of 36 cents a share - Earnings Preview
Brief: Vistagen Appoints Douglas J. Williamson To Its Board Of Directors